Alkermes
Alkermes plc, a leading biopharmaceutical company headquartered in Ireland, focuses on developing innovative therapies for central nervous system (CNS) disorders and addiction. Founded in 1987, Alkermes has established a strong presence in the global healthcare market, with significant operations in the United States and Europe. The company is renowned for its unique drug delivery technologies and a robust portfolio of products, including treatments for schizophrenia, depression, and opioid dependence. Alkermes' commitment to addressing complex medical needs has positioned it as a key player in the biopharmaceutical industry, with notable achievements in advancing patient care through its proprietary formulations. With a focus on scientific excellence and patient-centric solutions, Alkermes continues to drive innovation and improve outcomes for individuals affected by serious mental health conditions.
DitchCarbon Score
How does Alkermes's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alkermes's score of 30 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alkermes's reported carbon emissions
In 2024, Alkermes reported total carbon emissions of approximately 20,000,000 kg CO2e, a reduction from about 25,000,000 kg CO2e in 2023 and 30,000,000 kg CO2e in 2022. The emissions data for 2021 indicates a combined total of about 33,000,000 kg CO2e, comprising approximately 15,045,000 kg CO2e from Scope 1 and about 17,954,000 kg CO2e from Scope 2 emissions. This trend shows a significant decrease in emissions over the past three years. Alkermes has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company’s emissions data is not cascaded from a parent organization, indicating that it operates independently in its reporting. The company’s emissions per employee have also shown a downward trend, with figures of about 10,000 kg CO2e per employee in 2024, down from approximately 15,000 kg CO2e in 2023 and 2022. This reflects Alkermes's commitment to improving its operational efficiency and reducing its carbon footprint. Overall, Alkermes is making progress in reducing its carbon emissions, although it has yet to establish formal reduction targets or commitments within recognised frameworks.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 13,960,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | - | - |
| Scope 2 | 17,785,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | - | - |
| Scope 3 | - | - | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alkermes is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
